Lower concentrations of miR-148-5p after decitabine/carboplatin chemotherapy compared to baseline predicts worse progression free survival.

<p>For the Kaplan Meier progression free survival curve, patient samples were divided into 2 groups by the median value of the “–delta delta CT” values (post treatment value subtracted from baseline value). The log-rank test was between plasma miRNA concentration (high [red line] vs. low [black line]) with the time to non-response, and p value less than 0.05 was considered significant. The inset plots the raw C_T values of all patient samples for miR-148-5p, dashed lines—non-responders, solid lines—responders.</p

Study Design: Platinum resistant ovarian cancer subjects treated with decitabine and carboplatin.

<p>Fourteen platinum resistant ovarian cancer patients were treated with decitabine/carboplatin in a phase II clinical trial. For the first chemotherapy cycle, decitabine was given daily for 5 days; followed by carboplatin given on day 8. miRNA analysis used plasma samples collected at baseline (prior to start of cycle one treatment) and at day 29 (prior to start of second cycle).</p

Circulating miRNAs visually differentiate patients into different groups.

<p>Patients are numbered (left side of Fig 3) according to convention established, see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0141279#pone.0141279.g002" target="_blank">Fig 2</a>. Patients grouped visually based on clustering (red numbers = group 1, green numbers = group 2, and blue numbers = group 3). The clustering was based on similarity between the changes in miRNA concentrations between baseline (dC_{T baseline}) and after chemotherapy treatment (dC_{T treatment}). Blue = decreased concentrations after chemotherapy, Red = increased concentrations after treatment.</p